Insulet Price Target Lowered to $39.00 at Canaccord Genuity (PODD)
Analysts at Canaccord Genuity dropped their target price on shares of Insulet (NASDAQ:PODD) from $40.00 to $39.00 in a research report issued to clients and investors on Friday. Canaccord Genuity’s target price would indicate a potential upside of 12.65% from the company’s current price.
In other Insulet news, CEO Duane Desisto sold 20,000 shares of the stock on the open market in a transaction dated Friday, August 1st. The shares were sold at an average price of $34.23, for a total transaction of $684,600.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Separately, analysts at Barrington Research upgraded shares of Insulet from a “market perform” rating to an “outperform” rating in a research note on Thursday, May 15th. They now have a $40.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $45.33.
Shares of Insulet (NASDAQ:PODD) opened at 34.625 on Friday. Insulet has a one year low of $30.04 and a one year high of $51.31. The stock has a 50-day moving average of $37.63 and a 200-day moving average of $40.85. The company’s market cap is $1.919 billion.
Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.02. The company had revenue of $72.00 million for the quarter, compared to the consensus estimate of $72.94 million. During the same quarter in the previous year, the company posted ($0.20) earnings per share. The company’s revenue for the quarter was up 19.8% on a year-over-year basis. Analysts expect that Insulet will post $-0.16 EPS for the current fiscal year.
Insulet Corporation is primarily engaged in the development, manufacturing and sale of its OmniPod Insulin Management System (NASDAQ:PODD).
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.